Decoy Therapeutics (DCOY) versus Its Competitors Head to Head Comparison

Decoy Therapeutics (NASDAQ:DCOY) is one of 456 public companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its rivals? We will compare Decoy Therapeutics to related companies based on the strength of its institutional ownership, profitability, earnings, risk, analyst recommendations, valuation and dividends.

Profitability

This table compares Decoy Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-401.05%	-155.77%
Decoy Therapeutics Competitors	-2,662.14%	-363.93%	-42.95%

Risk and Volatility

Decoy Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Decoy Therapeutics’ rivals have a beta of 5.47, meaning that their average share price is 447% more volatile than the S&P 500.

Insider & Institutional Ownership

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 0.3% of Decoy Therapeutics shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Decoy Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Decoy Therapeutics	N/A	-$5.58 million	-0.02
Decoy Therapeutics Competitors	$432.12 million	-$67.78 million	-10.65

Decoy Therapeutics’ rivals have higher revenue, but lower earnings than Decoy Therapeutics. Decoy Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current recommendations for Decoy Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1	0	1	0	2.00
Decoy Therapeutics Competitors	4894	9963	15988	376	2.38

Decoy Therapeutics presently has a consensus price target of $2.50, indicating a potential upside of 238.39%. As a group, “Pharmaceutical Preparations” companies have a potential upside of 63.62%. Given Decoy Therapeutics’ higher probable upside, equities analysts plainly believe Decoy Therapeutics is more favorable than its rivals.

Summary

Decoy Therapeutics rivals beat Decoy Therapeutics on 9 of the 13 factors compared.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.